Successful treatment of a lung adenocarcinoma patient with a novel EGFR exon 20-ins mutation with afatinib

Abstract

To our knowledge, EGFR exon 20-ins mutation A767delinsASVD has never been reported, and the successful treatment of afatinib may provide a new therapeutic option for this type of exon 20 insertion mutations.